Wait-and-scan strategy feasible for head, neck paraganglioma

Wait-and-scan strategy feasible for head, neck paraganglioma

(HealthDay)—A wait-and-scan strategy seems to be feasible for patients with head and neck paraganglioma (PGL), according to a study published online July 10 in Head & Neck.

Thijs T.G. Jansen, from the Radboud University Medical Center in Nijmegen, Netherlands, and colleagues conducted a involving patients with head and neck PGL. The authors measured tumor growth in axial plane diameter and volume during a wait-and-scan period.

The researchers found that 44 percent of 59 jugulotympanic tumors, 71 carotid body tumors, and 29 vagal body tumors were growing (median growth rates, 0.41, 1.6, and 1.6 mm/year, respectively). There was a significant correlation for growth with age at presentation (odds ratio, 0.974; P < 0.05). Twenty complications were induced by 17 tumors; six of these were growing, and the rates were higher than in non-complication-inducing tumors (P = 0.016).

"The results of this study illustrate that a wait-and-scan policy is a feasible treatment option in cases for head and PGL, as it potentially prevents treatment-induced morbidity in the majority of patients, including those presenting larger tumors," the authors write. "Our results also suggest that radiological follow-up is not an optimal management strategy, because a large group of tumors were found not to grow, although they did elicit complications, in the main, years after the initial diagnosis."

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: Wait-and-scan strategy feasible for head, neck paraganglioma (2017, July 17) retrieved 19 June 2024 from https://medicalxpress.com/news/2017-07-wait-and-scan-strategy-feasible-neck-paraganglioma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Report describes primary clear cell sarcoma of head, neck

0 shares

Feedback to editors